Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | APLNR | P35414 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20920186 | 0.85 | CYP1A2 (0.49) | KDM4EMAPK1ALDH1A1MAPTLMNA | |
| SCHEMBL22263111 | 0.76 | KMT2A (0.40) | KDM4EALDH1A1MAPTTSHRLMNA | |
| SCHEMBL22263137 | 0.76 | MAPK1 (0.50) | MAPK1ALDH1A1TSHRLMNAMEN1 | |
| SCHEMBL20932675 | 0.75 | SIGMAR1 (0.41) | MEN1KMT2AGAA | |
| SCHEMBL19062036 | 0.74 | POLB (0.44) | KDM4EMAPK1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL20917818 | 0.74 | KMT2A (0.46) | KDM4EALDH1A1MAPTTSHRLMNA | |
| SCHEMBL20918028 | 0.73 | CYP1A2 (0.44) | KDM4EMAPK1ALDH1A1TSHRLMNA | |
| SCHEMBL20932242 | 0.73 | SIGMAR1 (0.41) | LMNAKMT2AGAACYP1A2CYP3A4 | |
| SCHEMBL22263119 | 0.72 | ALDH1A1 (0.43) | MAPK1ALDH1A1TSHRLMNAMEN1 | |
| SCHEMBL22263126 | 0.72 | HTT (0.41) | KDM4EMAPK1ALDH1A1MAPTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250092020-A1 | IDO/TDO Inhibitor | GENERAL INCORPORATED ASSOCIATION PHARMA VALLEY PROJECT SUPPORTING ORGANIZATION (JP) | 2025-03-20 | — | — | US | disclosed |
| US-12209079-B2 | IDO/TDO inhibitor | GENERAL INCORPORATED ASSOCIATION PHARMA VALLEY PROJECT SUPPORTING ORGANIZATION (JP) | 2025-01-28 | — | — | US | disclosed |
| US-20220380305-A1 | IDO/TDO Inhibitor | CANBAS CO., LTD. | 2022-12-01 | — | — | US | disclosed |
| US-20200239452-A1 | IDO/TDO Inhibitor | CANBAS CO., LTD. (JP) | 2020-07-30 | — | — | US | disclosed |
| US-20200239452-A1 | IDO/TDO Inhibitor | CANBAS CO., LTD. (JP) | 2020-07-30 | — | — | US | disclosed |
| WO-2019078246-A1 | IDO/TDO INHIBITOR | 一般社団法人ファルマバレープロジェクト支援機構 | 2019-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12209079-B2 | IDO/TDO inhibitor | IDO1, IDO2, TDO2 | KDM4E 1315/4885MAPK1 1048/4885ALDH1A1 3331/4885 |
| US-20200239452-A1 | IDO/TDO Inhibitor | IDO1, IDO2, TDO2 | KDM4E 1315/4885MAPK1 1048/4885ALDH1A1 3331/4885 |
| US-20250092020-A1 | IDO/TDO Inhibitor | IDO1, IDO2, TDO2 | KDM4E 1315/4885MAPK1 1048/4885ALDH1A1 3331/4885 |
| US-20220380305-A1 | IDO/TDO Inhibitor | IDO1, IDO2, TDO2 | KDM4E 751/4885MAPK1 831/4885ALDH1A1 3591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.